vs

Side-by-side financial comparison of Genius Sports Ltd (GENI) and Sotera Health Co (SHC). Click either name above to swap in a different company.

Genius Sports Ltd is the larger business by last-quarter revenue ($510.9M vs $303.4M, roughly 1.7× Sotera Health Co). Sotera Health Co runs the higher net margin — 11.5% vs -12.3%, a 23.8% gap on every dollar of revenue. Genius Sports Ltd produced more free cash flow last quarter ($69.6M vs $52.4M). Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 10.6%).

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

Sotera Health Co is a global provider of end-to-end medical safety solutions. It offers sterilization services, analytical laboratory testing, and regulatory advisory support for medical device manufacturers, pharmaceutical firms, and food and consumer product companies, helping clients meet industry standards and ensure product safety for end users worldwide.

GENI vs SHC — Head-to-Head

Bigger by revenue
GENI
GENI
1.7× larger
GENI
$510.9M
$303.4M
SHC
Higher net margin
SHC
SHC
23.8% more per $
SHC
11.5%
-12.3%
GENI
More free cash flow
GENI
GENI
$17.2M more FCF
GENI
$69.6M
$52.4M
SHC
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
10.6%
SHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GENI
GENI
SHC
SHC
Revenue
$510.9M
$303.4M
Net Profit
$-63.0M
$34.8M
Gross Margin
25.2%
54.7%
Operating Margin
-11.5%
23.2%
Net Margin
-12.3%
11.5%
Revenue YoY
4.6%
Net Profit YoY
182.8%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENI
GENI
SHC
SHC
Q4 25
$510.9M
$303.4M
Q3 25
$335.4M
$311.3M
Q2 25
$215.2M
$294.3M
Q1 25
$119.7M
$254.5M
Q4 24
$413.0M
$290.2M
Q3 24
$285.8M
$285.5M
Q2 24
$184.1M
$276.6M
Q1 24
$97.2M
$248.2M
Net Profit
GENI
GENI
SHC
SHC
Q4 25
$-63.0M
$34.8M
Q3 25
$48.4M
Q2 25
$-47.3M
$8.0M
Q1 25
$-25.5M
$-13.3M
Q4 24
$-85.5M
$12.3M
Q3 24
$-47.1M
$17.0M
Q2 24
$-35.5M
$8.8M
Q1 24
$-25.2M
$6.3M
Gross Margin
GENI
GENI
SHC
SHC
Q4 25
25.2%
54.7%
Q3 25
24.2%
57.0%
Q2 25
19.1%
56.6%
Q1 25
10.7%
53.2%
Q4 24
16.7%
56.6%
Q3 24
20.5%
55.4%
Q2 24
18.6%
55.2%
Q1 24
9.8%
51.2%
Operating Margin
GENI
GENI
SHC
SHC
Q4 25
-11.5%
23.2%
Q3 25
-15.3%
23.4%
Q2 25
-21.0%
6.4%
Q1 25
-20.3%
-5.8%
Q4 24
-18.0%
30.0%
Q3 24
-13.9%
28.2%
Q2 24
-16.8%
27.8%
Q1 24
-23.7%
21.4%
Net Margin
GENI
GENI
SHC
SHC
Q4 25
-12.3%
11.5%
Q3 25
15.5%
Q2 25
-22.0%
2.7%
Q1 25
-21.3%
-5.2%
Q4 24
-20.7%
4.2%
Q3 24
-16.5%
6.0%
Q2 24
-19.3%
3.2%
Q1 24
-25.9%
2.5%
EPS (diluted)
GENI
GENI
SHC
SHC
Q4 25
$0.12
Q3 25
$0.17
Q2 25
$0.03
Q1 25
$-0.05
Q4 24
$0.05
Q3 24
$0.06
Q2 24
$0.03
Q1 24
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENI
GENI
SHC
SHC
Cash + ST InvestmentsLiquidity on hand
$280.6M
$344.6M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$724.5M
$606.0M
Total Assets
$1.1B
$3.3B
Debt / EquityLower = less leverage
3.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENI
GENI
SHC
SHC
Q4 25
$280.6M
$344.6M
Q3 25
$110.2M
$299.2M
Q2 25
$110.2M
$332.4M
Q1 25
$110.2M
$304.4M
Q4 24
$100.3M
$277.2M
Q3 24
$100.3M
$306.7M
Q2 24
$100.3M
$246.1M
Q1 24
$100.3M
$261.1M
Total Debt
GENI
GENI
SHC
SHC
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.2B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.2B
Stockholders' Equity
GENI
GENI
SHC
SHC
Q4 25
$724.5M
$606.0M
Q3 25
$572.4M
$550.5M
Q2 25
$572.4M
$511.3M
Q1 25
$572.4M
$414.1M
Q4 24
$573.0M
$404.9M
Q3 24
$573.0M
$470.2M
Q2 24
$573.0M
$422.8M
Q1 24
$573.0M
$429.4M
Total Assets
GENI
GENI
SHC
SHC
Q4 25
$1.1B
$3.3B
Q3 25
$792.3M
$3.2B
Q2 25
$792.3M
$3.2B
Q1 25
$792.3M
$3.1B
Q4 24
$775.7M
$3.1B
Q3 24
$775.7M
$3.1B
Q2 24
$775.7M
$3.1B
Q1 24
$775.7M
$3.1B
Debt / Equity
GENI
GENI
SHC
SHC
Q4 25
3.53×
Q3 25
3.89×
Q2 25
4.34×
Q1 25
5.36×
Q4 24
5.49×
Q3 24
4.73×
Q2 24
5.26×
Q1 24
5.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENI
GENI
SHC
SHC
Operating Cash FlowLast quarter
$81.9M
$103.1M
Free Cash FlowOCF − Capex
$69.6M
$52.4M
FCF MarginFCF / Revenue
13.6%
17.3%
Capex IntensityCapex / Revenue
2.4%
16.7%
Cash ConversionOCF / Net Profit
2.96×
TTM Free Cash FlowTrailing 4 quarters
$33.5M
$149.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENI
GENI
SHC
SHC
Q4 25
$81.9M
$103.1M
Q3 25
$-4.8M
$71.2M
Q2 25
$-1.2M
$57.4M
Q1 25
$-14.6M
$55.5M
Q4 24
$14.9M
$55.7M
Q3 24
$-9.2M
$97.5M
Q2 24
$61.3M
Q1 24
$9.7M
Free Cash Flow
GENI
GENI
SHC
SHC
Q4 25
$69.6M
$52.4M
Q3 25
$-14.2M
$35.0M
Q2 25
$-5.8M
$26.2M
Q1 25
$-16.0M
$35.6M
Q4 24
$11.3M
$-10.2M
Q3 24
$-11.6M
$61.1M
Q2 24
$19.4M
Q1 24
$-25.2M
FCF Margin
GENI
GENI
SHC
SHC
Q4 25
13.6%
17.3%
Q3 25
-4.2%
11.2%
Q2 25
-2.7%
8.9%
Q1 25
-13.4%
14.0%
Q4 24
2.7%
-3.5%
Q3 24
-4.1%
21.4%
Q2 24
7.0%
Q1 24
-10.2%
Capex Intensity
GENI
GENI
SHC
SHC
Q4 25
2.4%
16.7%
Q3 25
2.8%
11.6%
Q2 25
2.1%
10.6%
Q1 25
1.2%
7.8%
Q4 24
0.9%
22.7%
Q3 24
0.9%
12.7%
Q2 24
15.2%
Q1 24
14.1%
Cash Conversion
GENI
GENI
SHC
SHC
Q4 25
2.96×
Q3 25
1.47×
Q2 25
7.21×
Q1 25
Q4 24
4.52×
Q3 24
5.73×
Q2 24
7.00×
Q1 24
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GENI
GENI

Segment breakdown not available.

SHC
SHC

Transferred At Point In Time$198.4M65%
Nelson Labs$55.2M18%
Nordion$49.8M16%

Related Comparisons